We investigated the effect of aminoguanidine (AG) administration on GBM thickness, glomerular heparan sulfate (HS) content, and urinary albumin and HS excretion in diabetic rats. After induction of diabetes, female Wistar rats were divided into 2 groups: Group AGDM (n 11) received lg/L aminoguanidine bicarbonate in drinking water, group DC (n 12) was given only tap water. Control rats received AG (group AGH, n 8) or tap water (group HC, n=8). At the end of a period of 8 weeks, urinary albumin and glycosaminoglycan (GAG) excretion was detected. GBM heparan sulfate distribution and count was determined under the electron microscope. The AGDM group had lower urinary albumin and GAG excretion than diabetic controls. GBM thickness was increased in diabetic rats compared to groups of AGDM and HC. In AGDM group alcian blue stained particle distribution and count in the GBM was similar to healthy controls. In conclusion AG prevents the decrease of anionic charged molecules in the GBM and GBM thickening. This can be one of the mechanisms by which AG decreases albuminuria in diabetic rats.
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INTRODUCTION
Thickening of the glomerular basement membrane (GBM) and albuminuria are the characteristic features of diabetic nephropathy. I1-31 Biochemical alterations of GBM subsequent to increased non-enzymatic glycation of structural proteins and formation of advanced glycosylation end products (AGE) have been invoked in the genesis of an altered size and charge-selective barrier. I4-61 Aminoguanidine, a hydrazine compound that inhibits glycosylation, prevents diabetic complications. It I141 urine glycosaminoglycan, which is the major elements of glomerular anionic barrier, as an marker of GAG loss from GBM, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Healthy control rats had a diffuse distribution pattern of alcian blue stained particles in the GBM (Fig. la) . In untreated diabetic rats, alcian blue stained particles were reduced along the basement membrane and subendothelial depositions of anionic particles were observed compared to the healthy control group (Fig. lb) (Fig. 2a) displayed less staining than healthy rats (Fig. 2b) [14, 24] AG treatment seems to protect the anionic content of both erythrocyte and glomerular basement membrane.
Our results suggest that treatment of diabetic rats with AG prevents this loss of glycosaminoglycans from the GBM. As it has been proposed before that an increased loss of glycosaminoglycans from the GBM alters glomerular charge selectivity, leading to loss of albumin in the urine. [15] [16] [17] 281 Results of biochemical (31) . Most remarkable finding is that AG treatment prevented the rise in glomerular protein kinase C activity. Prevention of albuminuria by aminoguanidine has also been associated with the normalization of glomerular protein kinase C (32) . In the view of these findings the exact mechanism still remains to be elucidated.
In conclusion, AG treatment reduces urinary albumin excretion, prevents GBM thickness and protects from the loss of GBM anionic content in diabetic rats. Preservation of anionic charges of the GBM seems to be one of the mechanisms by which aminoguanidine ameliorates the albuminuria in diabetic rats.
